Skip to main content
SpringerLink
Log in

Sektorenübergreifende interdisziplinäre Zusammenarbeit der Arbeitsgemeinschaft Internistische Onkologie in der Präzisionsonkologie

Cross-sectoral interdisciplinary collaboration of the Arbeitgemeinschaft Internistische Onkologie (AIO) in precision oncology

Der Onkologe volume 28, pages 6–16 (2022)Cite this article

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Abb. 1

Literatur

  1. Aga (2011) American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology 140:1084–1091

    Article  Google Scholar 

  2. Barlesi F, Drilon A, De Braud F et al (2019) Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): integrated analysis of ALKA-372-001, STARTRK‑1 and STARTRK‑2. Ann Oncol 30:ii48–ii49

    Article  Google Scholar 

  3. Bedard PL, Hyman DM, Davids MS et al (2020) Small molecules, big impact: 20 years of targeted therapy in oncology. Lancet 395:1078–1088

    Article  CAS  Google Scholar 

  4. Coleman HG, Bhat S, Murray LJ et al (2011) Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol 26:739–745

    Article  Google Scholar 

  5. Corley DA, Kubo A, Levin TR et al (2009) Race, ethnicity, sex and temporal differences in Barrett’s oesophagus diagnosis: a large community-based study, 1994–2006. Gut 58:182–188

    Article  CAS  Google Scholar 

  6. Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion—positive cancers in adults and children. N Engl J Med 378:731–739

    Article  CAS  Google Scholar 

  7. Falk GW (2002) Barrett’s esophagus. Gastroenterology 122:1569–1591

    Article  Google Scholar 

  8. Horak P, Heining C, Kreutzfeldt S et al (2021) Comprehensive genomic and transcriptomic analysis for guiding therapeutic decisions in patients with rare cancers. Cancer Discov 11(11):2780–2795. https://doi.org/10.1158/2159-8290.CD-21-0126

  9. Horak P, Klink B, Heining C et al (2017) Precision oncology based on omics data: the NCT Heidelberg experience. Int J Cancer 141:877–886

    Article  CAS  Google Scholar 

  10. Kreutzfeldt S, Apostolidis L, Oles M et al (2019) Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: updated results from the German NCT/DKTK MASTER trial. Ann Oncol 30:vii6

    Article  Google Scholar 

  11. Larson KL, Huang B, Weiss HL et al (2021) Clinical outcomes of molecular tumor boards: a systematic review. JCO Precis Oncol 9(5):PO.20.00495. https://doi.org/10.1200/PO.20.00495

    Article  Google Scholar 

  12. Leichsenring J, Horak P, Kreutzfeldt S et al (2019) Variant classification in precision oncology. Int J Cancer 145:2996–3010

    Article  CAS  Google Scholar 

  13. Marabelle A, Le DT, Ascierto PA et al (2020) Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 38:1–10

    Article  CAS  Google Scholar 

  14. MD Anderson Cancer Center Institute for Personalized Cancer Therapy. https://pct.mdanderson.org

  15. Moscow JA, Fojo T, Schilsky RL (2018) The evidence framework for precision cancer medicine. Nat Rev Clin Oncol 15:183–192

    Article  Google Scholar 

  16. Quante M (2020) BarrettNET – Risikoevaluation und Prävention von Adenokarzinomen des Ösophagus. In: Forum. Springer, Berlin Heidelberg, S 342–344

    Google Scholar 

  17. Quante M, Bhagat G, Abrams JA et al (2012) Bile acid and inflammation activate gastric cardia stem cells in a mouse model of Barrett-like metaplasia. Cancer Cell 21(1):36–51. https://doi.org/10.1016/j.ccr.2011.12.004

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Schmidt M, Ankerst DP, Chen Y et al (2020) Epidemiological risk factors in a comparison of a Barrett Esophagus Registry (BarretNET) and a case control population in Germany. Cancer Prev Res 13(4):377–384. https://doi.org/10.1158/1940-6207.CAPR-19-0474

    Article  Google Scholar 

  19. Stenzinger A, Van Tilburg CM, Tabatabai G et al (2021) Diagnosis and therapy of tumors with NTRK gene fusion. Pathologe 42:103–115

    Article  Google Scholar 

  20. Wani S, Falk GW, Post J et al (2011) Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology 141:1179–1186, 1186.e1

    Article  Google Scholar 

  21. Westphalen BC, Bokemeyer C, Büttner R et al (2020) Conceptual framework for precision cancer medicine in Germany: consensus statement of the Deutsche Krebshilfe working group ‘Molecular Diagnostics and Therapy. Eur J Cancer 135:1–7

    Article  Google Scholar 

  22. Wiethaler M, Slotta-Huspenina J, Brandtner A et al (2019) BarrettNET—a prospective registry for risk estimation of patients with Barrett’s esophagus to progress to adenocarcinoma. Dis Esophagus 32(8):doz024. https://doi.org/10.1093/dote/doz024

    Article  PubMed  Google Scholar 

  23. Annals of Oncology (2021) 32 (suppl_5):S530–S582. https://doi.org/10.1016/annonc/annonc698

Download references

Author information

Authors and Affiliations

  1. Medizinische Klinik und Poliklinik III und CCC München, Klinikum der Universität München, LMU München, München, Deutschland

    Christoph-Benedikt Westphalen

  2. Klinik für Innere Medizin II, Gastrointestinale Onkologie, Universitätsklinikum Freiburg, Freiburg, Deutschland

    Michael Quante

  3. zielGENnau e. V., Köln, Deutschland

    Bärbel Söhlke

  4. Patientenvertretung, Centrum für Integrierte Onkologie, Uniklinik Köln, Köln, Deutschland

    Bärbel Söhlke

  5. German Sarcoma Foundation, Wölfersheim, Deutschland

    Markus Wartenberg

  6. Patientenvertretung, Westdeutsches Tumorzentrum, Essen, Deutschland

    Markus Wartenberg

  7. Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Deutschland

    Wolfgang Knauf

  8. Gemeinschaftspraxis Hämatologie-Onkologie, Dresden, Deutschland

    Thomas Illmer

  9. Hämatologisch-Onkologische Praxis Eppendorf, Hamburg, Deutschland

    Eray Gökkurt

  10. Institut für Pathologie, Ruhr Universität Bochum, Bochum, Deutschland

    Andrea Tannapfel

  11. Universitätsklinik für Innere Medizin, Pius-Hospital Oldenburg, Oldenburg, Deutschland

    Frank Griesinger

  12. Klinik für Hämatologie, Onkologie und Palliativmedizin, Ruhr-Universität Bochum, Bochum, Deutschland

    Anke Reinacher-Schick

  13. DKFZ-Hector Krebsinstitut an der UMM, Mannheim, Deutschland

    Sonja Loges

  14. Abteilung für Personalisierte Medizinische Onkologie (A420), Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Deutschland

    Sonja Loges

  15. Abteilung für Personalisierte Onkologie, Universitätsmedizin Mannheim, Medizinische Fakultät Mannheim, Universität Heidelberg, Heidelberg, Deutschland

    Sonja Loges

Authors
  1. Christoph-Benedikt Westphalen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Quante
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Bärbel Söhlke
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Markus Wartenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wolfgang Knauf
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thomas Illmer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Eray Gökkurt
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Andrea Tannapfel
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Frank Griesinger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Anke Reinacher-Schick
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Sonja Loges
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sonja Loges.

Ethics declarations

Interessenkonflikt

C.-B. Westphalen, M. Quante, B. Söhlke, M. Wartenberg, W. Knauf, T. Illmer, E. Gökkurt, A. Tannapfel, F. Griesinger, A. Reinacher-Schick und S. Loges geben an, dass kein Interessenkonflikt besteht.

Für diesen Beitrag wurden von den Autoren keine Studien an Menschen oder Tieren durchgeführt. Für die aufgeführten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.

Additional information

figure qr

QR-Code scannen & Beitrag online lesen

Rights and permissions

Reprints and Permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Westphalen, CB., Quante, M., Söhlke, B. et al. Sektorenübergreifende interdisziplinäre Zusammenarbeit der Arbeitsgemeinschaft Internistische Onkologie in der Präzisionsonkologie. Onkologe 28 (Suppl 1), 6–16 (2022). https://doi.org/10.1007/s00761-021-01090-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-021-01090-8

search

Navigation